Astellas Pharma Statistics
Want to see JP:4503 full AI Analyst Report?
Astellas Pharma (4503) Stock Statistics & Valuation Metrics
Total Valuation
Astellas Pharma has a market cap or net worth of JPY 4.45T. The enterprise value is JPY 4.36T.
- Market Cap
- JPY 4.45T
- Enterprise Value
- JPY 4.36T
Share Statistics
Astellas Pharma has 1,809,663,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,809,663,100
- Owned by Insiders
- ―
- Owned by Institutions
- 24.13%
Financial Efficiency
Astellas Pharma’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 12.52%.
- Return on Equity (ROE)
- 0.16
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 12.52%
- Return on Capital Employed (ROCE)
- 0.18
- Revenue Per Employee
- 151.73M
- Profits Per Employee
- 20.68M
- Employee Count
- 14,099
- Asset Turnover
- 0.60
- Inventory Turnover
- 1.64
Valuation Ratios
The current PE Ratio of Astellas Pharma is 12.31. Astellas Pharma’s PEG ratio is 0.06.
- PE Ratio
- 12.31
- PS Ratio
- 2.00
- PB Ratio
- 2.40
- Price to FCF
- 9.55
- Price to Operating Cash Flow
- 8.60
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, Astellas Pharma had revenue of 2.14T and earned 291.54B in profits. Earnings per share was 162.77.
- Revenue
- 2.14T
- Gross Profit
- 1.59T
- Operating Income
- 419.70B
- Pretax Income
- 376.59B
- Net Income
- 291.54B
- EBITDA
- 585.25B
- Earnings Per Share (EPS)
- 162.77
Cash Flow
In the last 12 months, operating cash flow was 553.53B and capital expenditures -56.18B, giving a free cash flow of 497.35B billion.
- Operating Cash Flow
- 553.53B
- Free Cash Flow
- 497.35B
- Free Cash Flow per Share
- 276.91
Dividends & Yields
Astellas Pharma pays an annual dividend of JPY 40.00, resulting in a dividend yield of 3.20%
- Dividend Per Share
- JPY 40.00
- Dividend Yield
- 3.20%
- Payout Ratio
- 47.92%
- Free Cash Flow Yield
- 10.58%
- Earnings Yield
- 8.19%
Stock Price Statistics
- Beta
- 0.73
- 52-Week Price Change
- 41.88%
- 50-Day Moving Average
- 2362.22
- 200-Day Moving Average
- 2302.37
- Relative Strength Index (RSI)
- 52.05
- Average Volume (3m)
- 6.00M
Important Dates
Astellas Pharma upcoming earnings date is Feb 08, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 08, 2027
- Ex-Dividend Date
- Sep 29, 2026
Financial Position
Astellas Pharma as a current ratio of 1.17, with Debt / Equity ratio of 30.91%
- Current Ratio
- 1.17
- Quick Ratio
- 0.90
- Debt to Market Cap
- 0.13
- Net Debt to EBITDA
- 0.49
- Interest Coverage Ratio
- 29.83
Taxes
In the past 12 months, Astellas Pharma has paid 85.01B in taxes.
- Income Tax
- 85.01B
- Effective Tax Rate
- 0.23
Enterprise Valuation
Astellas Pharma EV to EBITDA ratio is 6.60, with an EV/FCF ratio of 9.82.
- EV to Sales
- 2.05
- EV to EBITDA
- 6.60
- EV to Free Cash Flow
- 9.82
- EV to Operating Cash Flow
- 8.83
Balance Sheet
Astellas Pharma has JPY 238.23B in cash and marketable securities with JPY 424.92B in debt, giving a net cash position of -JPY 186.69B billion.
- Cash & Marketable Securities
- JPY 238.23B
- Total Debt
- JPY 424.92B
- Net Cash
- -JPY 186.69B
- Net Cash Per Share
- -JPY 103.16
- Tangible Book Value Per Share
- JPY 340.34
Margins
Gross margin is 74.89%, with operating margin of 23.37%, and net profit margin of 16.20%.
- Gross Margin
- 74.89%
- Operating Margin
- 23.37%
- Pretax Margin
- 20.98%
- Net Profit Margin
- 16.20%
- EBITDA Margin
- 31.09%
- EBIT Margin
- 22.74%
Analyst Forecast
The average price target for Astellas Pharma is JPY 2,515.00, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- JPY 2,515.00
- Price Target Upside
- 1.76% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 6
- Revenue Growth Forecast
- 18.60%
- EPS Growth Forecast
- 208.60%
Scores
- Smart Score
- ―
- AI Score
- 77
